Glenmark will market this product upon receiving final approval of its Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg ANDA. According to IMS Health sales data for the 12 month period ending April 2016, the Benicar® Tablet market1 achieved annual sales of approximately $1.05 billion.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the US Food & Drug Administration (U.S. FDA) for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, the generic version of Benicar Tablets of Daiichi Sankyo, Inc.
Glenmark will market this product upon receiving final approval of its Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg ANDA. According to IMS Health sales data for the 12 month period ending April 2016, the Benicar® Tablet market1 achieved annual sales of approximately $1.05 billion.
Glenmark’s current portfolio consists of 114 products authorized for distribution in the U.S. marketplace and 62 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Ltd is currently trading at Rs. 751.35, down by Rs. 23.55 or 3.04% from its previous closing of Rs. 774.9 on the BSE.
The scrip opened at Rs. 765 and has touched a high and low of Rs. 767.4 and Rs. 749 respectively. So far 70232(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 21865.06 crore.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.5 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs. 782 and Rs. 746.25 respectively.
The promoters holding in the company stood at 46.48 % while Institutions and Non-Institutions held 41.92 % and 11.6 % respectively.
The stock is currently trading below its 200 DMA.
Glenmark will market this product upon receiving final approval of its Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg ANDA. According to IMS Health sales data for the 12 month period ending April 2016, the Benicar® Tablet market1 achieved annual sales of approximately $1.05 billion.
Glenmark’s current portfolio consists of 114 products authorized for distribution in the U.S. marketplace and 62 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Ltd is currently trading at Rs. 751.35, down by Rs. 23.55 or 3.04% from its previous closing of Rs. 774.9 on the BSE.
The scrip opened at Rs. 765 and has touched a high and low of Rs. 767.4 and Rs. 749 respectively. So far 70232(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 21865.06 crore.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.5 on 12-Feb-2016. Last one week high and low of the scrip stood at Rs. 782 and Rs. 746.25 respectively.
The promoters holding in the company stood at 46.48 % while Institutions and Non-Institutions held 41.92 % and 11.6 % respectively.
The stock is currently trading below its 200 DMA.
No comments:
Post a Comment